Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 2, 2013, Pages 115-120

  Van Duin, David ^a   Kaye, Keith S ^b   Neuner, Elizabeth A ^a   Bonomo, Robert A ^c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Carbapenem resistance; Enterobacteriaceae; Mortality; Multidrug resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; COLISTIMETHATE; COLISTIN; FOSFOMYCIN; FOSFOMYCIN SODIUM; GENTAMICIN; MEROPENEM; PLAZOMICIN; POLYMYXIN; POLYMYXIN B; TEMOCILLIN; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; CYSTITIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EOSINOPHIL; GASTROINTESTINAL SYMPTOM; HUMAN; INNER EAR DISEASE; LEUKOCYTE COUNT; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PHLEBITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN INFECTION; SYSTEMIC DISEASE; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT INFECTION; VOMITING;

BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 84872498847     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.11.009     Document Type: Review

References (72)

1. Alexander B.T., Marschall J., et al. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012, 34:1314-1323.
2. Ben-David D., Kordevani R., et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012, 18:54-60.
3. Boelaert J., Daneels R., et al. The pharmacokinetics of temocillin in patients with normal and impaired renal function. J Antimicrob Chemother 1983, 11:349-356.
4. Borer A., Saidel-Odes L., et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976.
5. Borsa F., Leroy A., et al. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults. Antimicrob Agents Chemother 1988, 32:938-941.
6. Bratu S., Landman D., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005, 165:1430-1435.
7. Bulik C.C., Nicolau D.P. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:3002-3004.
8. Cai Y., Wang R., et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011, 55:1162-1172.
9. Chow J.W., Yu V.L. Combination antibiotic therapy versus monotherapy for Gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999, 11:7-12.
10. Couet W., Gregoire N., et al. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012, 18:30-39.
11. Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 2011, 17:1135-1141.
12. Daikos G.L., Petrikkos P., et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009, 53:1868-1873.
13. Dalfino L., Puntillo F., et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012, 54:1720-1726.
14. Dinh A., Salomon J., et al. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis 2012, 44:182-189.
15. Dudhani R.V., Turnidge J.D., et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010, 54:1117-1124.
16. Edson R.S., Terrell C.L. The aminoglycosides. Mayo Clin Proc 1999, 74:519-528.
17. Endimiani A., Hujer K.M., et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009, 53:4504-4507.
18. Falagas M.E., Bliziotis I.A., et al. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005, 5:24.
19. Falagas M.E., Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005, 40:1333-1341.
20. Garonzik S.M., Li J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294.
21. Gould J.G., Meikle G., et al. Temocillin concentrations in human tissues. Drugs 1985, 29(Suppl 5):167-170.
22. Hartzell J.D., Neff R., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728.
23. Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010, 12:12. [Epub April 8, 2010].
24. Holloway K.P., Rouphael N.G., et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006, 40:1939-1945.
25. Huttner B., Jones M., et al. Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs Medical Centers, 2005-2010. PLoS One 2012, 7:e36649.
26. Hyle E.P., Ferraro M.J., et al. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. Infect Control Hosp Epidemiol 2010, 31:1242-1249.
27. Jin Z., Yang Y.X., et al. Potato (Solanum tuberosum L. cv. Gogu valley) protein as a novel antimicrobial agent in weanling pigs. J Anim Sci 2008, 86:1562-1572.
28. Karageorgopoulos D.E., Wang R., et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012, 67:255-268.
29. Ku K., Pogue J.M., et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 2012, 40(10):983-987.
30. Kuhnen E., Pfeifer G., et al. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection 1987, 15:422-424.
31. Kwon J.A., Lee J.E., et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010, 35:473-477.
32. Lautenbach E., Han J., et al. Colonization with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in long-term care facility residents. Infect Control Hosp Epidemiol 2012, 33:302-304.
33. Li J., Milne R.W., et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001, 761:167-175.
34. Li J., Milne R.W., et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002, 46:3304-3307.
35. Li J., Milne R.W., et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004, 53:837-840.
36. Linden P.K., Kusne S., et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003, 37:e154-e160.
37. Livermore D.M., Warner M., et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011, 37:415-419.
38. Marchaim D., Chopra T., et al. Outcomes and genetic relatedness of carbapenem-resistant Enterobacteriaceae at Detroit medical center. Infect Control Hosp Epidemiol 2011, 32:861-871.
39. Matzi V., Lindenmann J., et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010, 65:995-998.
40. Meagher A.K., Ambrose P.G., et al. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52:165-171.
41. Michalopoulos A.S., Livaditis I.G., et al. The revival of fosfomycin. Int J Infect Dis 2011, 15:e732-e739.
42. Moore R.D., Lietman P.S., et al. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
43. Mouloudi E., Protonotariou E., et al. Bloodstream infections caused by metallo-beta-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010, 31:1250-1256.
44. Neuner E.A., Yeh J.-Y., et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 2011, 69:357-362.
45. Nix D.E., Matthias K.R. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother 2010, 65:1311-1312.
46. Ouderkirk J.P., Nord J.A., et al. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003, 47:2659-2662.
47. Perez F., Endimiani A., et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010, 65:1807-1818.
48. Pogue J.M., Lee J., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011, 53:879-884.
49. Prabaker K., Weinstein R.A. Trends in antimicrobial resistance in intensive care units in the United States. Curr Opin Crit Care 2011, 17:472-479.
50. Prasad P., Sun J., et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012, 54:1699-1709.
51. Qureshi Z.A., Paterson D.L., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012, 56:2108-2113.
52. Rhomberg P.R., Jones R.N. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009, 65:414-426.
53. Rodvold K.A., Gotfried M.H., et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006, 58:1221-1229.
54. Roussos N., Karageorgopoulos D.E., et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009, 34:506-515.
55. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002, 136:834-844.
56. Satlin M.J., Kubin C.J., et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011, 55:5893-5899.
57. Schintler M.V., Traunmuller F., et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 2009, 64:574-578.
58. Souli M., Galani I., et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010, 50:364-373.
59. Spellberg B., Blaser M., et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011, 52(Suppl. 5):S397-S428.
60. Stuart R.L., Kotsanas D., et al. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust 2011, 195:530-533.
61. Tam V.H., Schilling A.N., et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:3624-3630.
62. Tarchini G. Tigecycline and bacteremia-the dangers of post hoc analysis of pooled data. Clin Infect Dis 2010, 51:867-868. [author reply 868].
63. Tasina E., Haidich A.B., et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011, 11:834-844.
64. Tumbarello M., Viale P., et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55(7):943-950.
65. van Duijn P.J., Dautzenberg M.J., et al. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 2011, 17:658-665.
66. Wang L., Lansing B., et al. Infection rate and colonization with antibiotic-resistant organisms in skilled nursing facility residents with indwelling devices. Eur J Clin Microbiol Infect Dis 2012, 31(8):1797-1805.
67. Wisher D. Martindale: the complete drug reference, 37th edition. J Med Libr Assoc 2012, 100:U75-U110.
68. Won S.Y., Munoz-Price L.S., et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011, 53:532-540.
69. Yahav D., Lador A., et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011, 66:1963-1971.
70. Yousef J.M., Chen G., et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011, 55:4044-4049.
71. Yousef J.M., Chen G., et al. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012, 67:452-459.
72. Zarkotou O., Pournaras S., et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011, 17:1798-1803.